AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10468081 — intervention group
Group type: COMPARATOR
Intervention: Control (inhibited pacing)
Number of subjects: 19
Study 10468081 — intervention group
Group type: EXPERIMENTAL
Intervention: Biatrial pacing vs Right atrial pacing
Number of subjects: 19
Study 10468081 — intervention group
Group type: COMPARATOR
Intervention: Control vs Right atrial pacing
Number of subjects: 19
Study 10468081 — intervention group
Group type: COMPARATOR
Intervention: Control vs Biatrial pacing
Number of subjects: 19
Study 7540397 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin (30,000 KIU/kg in CPB priming volume and 7,500 KIU/kg intravenously each hour during CPB)
Number of subjects: 20
Study 7540397 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 20
Study 7540397 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin
Number of subjects: 20
Study 2228396 — intervention group
Group type: EXPERIMENTAL
Intervention: dexfenfluramine (30 mg/day)
Number of subjects: 10
Study 2228396 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 91027 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide
Number of subjects: 192
Study 31915043 — intervention group
Group type: EXPERIMENTAL
Intervention: Staying UpRight exercise program (strength and balance exercises)
Number of subjects: 528
Study 31915043 — intervention group
Group type: COMPARATOR
Intervention: Seated exercise program (control group)
Number of subjects: 528
Study 31915043 — intervention group
Group type: EXPERIMENTAL
Intervention: Staying UpRight exercise program
Number of subjects: 528
Study 31915043 — intervention group
Group type: COMPARATOR
Intervention: Seated exercise program
Number of subjects: 528
Study 31658479 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional treatment strategies for secondary MR
Number of subjects: 0
Study 31658479 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-based mitral valve prosthesis
Number of subjects: 0
Study 28148502 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric administration of 1 μmol DB/kg
Number of subjects: 39
Study 26696482 — intervention group
Group type: EXPERIMENTAL
Intervention: Packed group (nasal packing with Merocel)
Number of subjects: 112
Study 26696482 — intervention group
Group type: COMPARATOR
Intervention: Non-packed group (no nasal packing)
Number of subjects: 112
Study 23953358 — intervention group
Group type: EXPERIMENTAL
Intervention: NEAT Girls intervention
Number of subjects: 357
Study 21029121 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular pacing
Number of subjects: 85
Study 21029121 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 85
Study 19144382 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual microscopy
Number of subjects: 14
Study 19144382 — intervention group
Group type: COMPARATOR
Intervention: Traditional glass microscopy
Number of subjects: 14
Study 16904537 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg/kg)
Number of subjects: 42
Study 16904537 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 42
Study 16904537 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (10 mg/l)
Number of subjects: 42
Study 16904537 — intervention group
Group type: COMPARATOR
Intervention: Ischemic Preconditioning (IP)
Number of subjects: 42
Study 15167288 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-nucleoside therapy (ZDV, 3TC, and ddI)
Number of subjects: 184
Study 15167288 — intervention group
Group type: COMPARATOR
Intervention: Dual-nucleoside therapy (ZDV and 3TC or ddI and d4T)
Number of subjects: 184
Study 11384568 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% three times daily
Number of subjects: 30
Study 11384568 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% twice daily
Number of subjects: 30
Study 11384568 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate 0.5% twice daily
Number of subjects: 30
Study 9205014 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful rescue PTCA
Number of subjects: 402
Study 9205014 — intervention group
Group type: EXPERIMENTAL
Intervention: Failed rescue PTCA
Number of subjects: 402
Study 9205014 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue PTCA (successes and failures combined)
Number of subjects: 402
Study 9205014 — intervention group
Group type: COMPARATOR
Intervention: No rescue PTCA
Number of subjects: 402
Study 9205014 — intervention group
Group type: COMPARATOR
Intervention: Patients with patent arteries
Number of subjects: 402
Study 7804524 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG surgery
Number of subjects: 2649
Study 2885337 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone (25 mU/m2 X min)
Number of subjects: 8
Study 2885337 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin with SRIH (250 micrograms/h) and glucagon replacement (0.4 ng/kg X min)
Number of subjects: 8
Study 30255302 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (Zocor – MSD; 40 mg daily)
Number of subjects: 50
Study 30255302 — intervention group
Group type: COMPARATOR
Intervention: Control (simvastatin-untreated)
Number of subjects: 50
Study 29626465 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month adjuvant androgen-deprivation therapy (ADT)
Number of subjects: 38
Study 29626465 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvant ADT
Number of subjects: 38
Study 27367821 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise counseling plus pedometer
Number of subjects: 0
Study 27367821 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 27367821 — intervention group
Group type: COMPARATOR
Intervention: Pedometer use
Number of subjects: 0
Study 25391138 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginate beads mixed into jelly
Number of subjects: 15
Study 25391138 — intervention group
Group type: COMPARATOR
Intervention: Ferrous gluconate in a capsule
Number of subjects: 15
Study 25391138 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meals with calcium (n = 9)
Number of subjects: 15
Study 25391138 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginate and cola jelly in Caco-2 cells
Number of subjects: 15
Study 25391138 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cola jelly and calcium
Number of subjects: 15
Study 22678316 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 19
Study 22678316 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 19
Study 22678316 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (19 patients)
Number of subjects: 19
Study 20299316 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin monotherapy in Study 305
Number of subjects: 1864
Study 20299316 — intervention group
Group type: COMPARATOR
Intervention: Treatment of physician's choice in Study 305
Number of subjects: 1864
Study 20299316 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin in Study 301
Number of subjects: 1864
Study 20299316 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine in Study 301
Number of subjects: 1864
Study 18585071 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency magnetic field exposure for three weeks, 20 min a day, five days a week.
Number of subjects: 61
Study 18585071 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure for three weeks, 20 min a day, five days a week.
Number of subjects: 61
Study 18585071 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency magnetic field exposure
Number of subjects: 61
Study 18585071 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 61
Study 15631247 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0
Study 15631247 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 0
Study 11713438 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (mailed postcard and up to 4 telephone calls)
Number of subjects: 603
Study 11713438 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 603
Study 11713438 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 603
Study 9386673 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV‐TV (4 x 10(5) plaque‐forming units per dose)
Number of subjects: 1185
Study 9386673 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV‐S1 (4 x 10(5) plaque‐forming units per dose)
Number of subjects: 1185
Study 9386673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1185
Study 8195908 — intervention group
Group type: EXPERIMENTAL
Intervention: Materials-based educational intervention (48-page prevention guidebook)
Number of subjects: 200
Study 8195908 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 200
Study 3585121 — intervention group
Group type: EXPERIMENTAL
Intervention: No serum in the insemination and growth medium (experimental group)
Number of subjects: 29
Study 3585121 — intervention group
Group type: COMPARATOR
Intervention: 10% serum added to the insemination and growth medium (control group)
Number of subjects: 29
Study 30078257 — intervention group
Group type: EXPERIMENTAL
Intervention: hrHPV infected subjects
Number of subjects: 18
Study 30078257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical carcinoma group
Number of subjects: 18
Study 30078257 — intervention group
Group type: COMPARATOR
Intervention: Normal vaginal flora
Number of subjects: 18
Study 30078257 — intervention group
Group type: COMPARATOR
Intervention: Four groups (Alpha diversity)
Number of subjects: 18
Study 30078257 — intervention group
Group type: EXPERIMENTAL
Intervention: hrHPV infected cervical discharge
Number of subjects: 18
Study 27146272 — intervention group
Group type: EXPERIMENTAL
Intervention: New or persistent Cornell product LVH at year-3
Number of subjects: 377
Study 24562510 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate (CH)
Number of subjects: 275
Study 24562510 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (MD)
Number of subjects: 275
Study 22411021 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly automated telephone calls reminding to take glaucoma medications and a 1-time educational session with a physician.
Number of subjects: 80
Study 22411021 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention group (no reminders or educational session).
Number of subjects: 80
Study 22411021 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (after the midstudy visit).
Number of subjects: 80
Study 22411021 — intervention group
Group type: COMPARATOR
Intervention: Intervention and nonintervention groups (before and after the midstudy intervention visit).
Number of subjects: 80
Study 22411021 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality scales for depression and hypochondriasis.
Number of subjects: 80
Study 21109134 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral recumbent head-down position
Number of subjects: 347
Study 21109134 — intervention group
Group type: COMPARATOR
Intervention: Lateral recumbent horizontal position
Number of subjects: 347
Study 21109134 — intervention group
Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 347
Study 18440179 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral carotid artery stenting (CAS)
Number of subjects: 747
Study 18440179 — intervention group
Group type: COMPARATOR
Intervention: Pivotal group (control)
Number of subjects: 747
Study 16132877 — intervention group
Group type: EXPERIMENTAL
Intervention: ML-1 standardized mistletoe extract (1 ng/kg body weight, injected subcutaneously twice weekly for 60 weeks)
Number of subjects: 399
Study 16132877 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment specified)
Number of subjects: 399
Study 16132877 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients undergoing radiotherapy
Number of subjects: 399
Study 15170391 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4
Number of subjects: 40
Study 15170391 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid solution
Number of subjects: 40
Study 10910490 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil infusion titrated to autonomic responses
Number of subjects: 50
Study 10910490 — intervention group
Group type: COMPARATOR
Intervention: desflurane titrated to autonomic responses
Number of subjects: 50
Study 8764802 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine plus hydrocortisone
Number of subjects: 20
Study 8764802 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine alone
Number of subjects: 20
Study 8764802 — intervention group
Group type: COMPARATOR
Intervention: Placebos (oral and intravenous)
Number of subjects: 20
Study 1395837 — intervention group
Group type: EXPERIMENTAL
Intervention: NIAID vaccine
Number of subjects: 99
Study 1395837 — intervention group
Group type: EXPERIMENTAL
Intervention: BBPRI vaccine
Number of subjects: 99
Study 1395837 — intervention group
Group type: EXPERIMENTAL
Intervention: BBPRI vaccine plus HBIG
Number of subjects: 99
Study 1395837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 3906783 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine 2% with adrenaline 1:200,000
Number of subjects: 20
Study 3906783 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 2% with adrenaline 1:200,000
Number of subjects: 20
Study 30800684 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient diabetes self-management education programme
Number of subjects: 60
Study 30800684 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular health education programmes)
Number of subjects: 60
Study 29332470 — intervention group
Group type: EXPERIMENTAL
Intervention: CORE intervention (NMT program)
Number of subjects: 474
Study 29332470 — intervention group
Group type: COMPARATOR
Intervention: SHAM intervention
Number of subjects: 474
Study 26948755 — intervention group
Group type: EXPERIMENTAL
Intervention: eCHECKUP TO GO-marijuana
Number of subjects: 123
Study 26948755 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 123
Study 24418413 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring group
Number of subjects: 32
Study 24418413 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 22369287 — intervention group
Group type: EXPERIMENTAL
Intervention: vildagliptin 50 mg bid
Number of subjects: 438
Study 22369287 — intervention group
Group type: EXPERIMENTAL
Intervention: vildagliptin 50 mg qd
Number of subjects: 438
Study 22369287 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 438
Study 20800079 — intervention group
Group type: COMPARATOR
Intervention: Multi-media intervention for physical activity, fruit and vegetable consumption, and limited TV viewing
Number of subjects: 1800
Study 17690600 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 62
Study 17690600 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 62
Study 17690600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 12916869 — intervention group
Group type: EXPERIMENTAL
Intervention: Iseganan 9 mg, oral rinse, swished/swallowed 6 times daily for 21-28 days
Number of subjects: 323
Study 12916869 — intervention group
Group type: COMPARATOR
Intervention: Placebo, oral rinse, swished/swallowed 6 times daily for 21-28 days
Number of subjects: 323
Study 12916869 — intervention group
Group type: EXPERIMENTAL
Intervention: Iseganan
Number of subjects: 323
Study 12916869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study 10617707 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam nasal spray (0.2 mg/kg body weight)
Number of subjects: 43
Study 10617707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 8885584 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (individual titration to 'best' dose)
Number of subjects: 576
Study 1524922 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg twice daily
Number of subjects: 135
Study 1524922 — intervention group
Group type: COMPARATOR
Intervention: Wedge mastectomy
Number of subjects: 135
Study 3878631 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapies including Sucralfate
Number of subjects: 8
Study 3878631 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine, Pirenzepine, Ranitidine (used alone)
Number of subjects: 8
Study 31770139 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 10 mg
Number of subjects: 483
Study 31770139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483
Study 28472693 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH (100μg)
Number of subjects: 31
Study 28472693 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 31
Study 25932849 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g cefazolin
Number of subjects: 57
Study 25932849 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g cefazolin
Number of subjects: 57
Study 23357835 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (Rapiflox®)
Number of subjects: 20
Study 23357835 — intervention group
Group type: COMPARATOR
Intervention: Reference product (Avelox®)
Number of subjects: 20
Study 23357835 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Test/Reference
Number of subjects: 20
Study 21278001 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-designed education program on co-enrollment
Number of subjects: 398
Study 21278001 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared electronic database between research units
Number of subjects: 398
Study 21278001 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviews with ineligible enrolled women
Number of subjects: 398
Study 19583757 — intervention group
Group type: EXPERIMENTAL
Intervention: Low educational level
Number of subjects: 1090
Study 17407626 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram 20 mg/day
Number of subjects: 466
Study 17407626 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram 10 mg/day
Number of subjects: 466
Study 17407626 — intervention group
Group type: EXPERIMENTAL
Intervention: paroxetine 40 mg/day
Number of subjects: 466
Study 17407626 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 466
Study 15159237 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruveg group (600 g fruit and vegetables/d)
Number of subjects: 43
Study 15159237 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplement group (vitamin pill corresponding to 600 g fruit and vegetables)
Number of subjects: 43
Study 15159237 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (placebo pill)
Number of subjects: 43
Study 15159237 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruveg group
Number of subjects: 43
Study 15159237 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplement group
Number of subjects: 43
Study 15159237 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruveg group and Supplement group
Number of subjects: 43
Study 10960628 — intervention group
Group type: COMPARATOR
Intervention: Unopposed E2 1 mg
Number of subjects: 1176
Study 10960628 — intervention group
Group type: EXPERIMENTAL
Intervention: E2-norethindrone acetate 0.1 mg
Number of subjects: 1176
Study 10960628 — intervention group
Group type: EXPERIMENTAL
Intervention: E2-norethindrone acetate 0.25 mg
Number of subjects: 1176
Study 10960628 — intervention group
Group type: EXPERIMENTAL
Intervention: E2-norethindrone acetate 0.5 mg
Number of subjects: 1176
Study 8829097 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 14
Study 8829097 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 14
Study 8829097 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 14
Study 1310645 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya fibers (7 g)
Number of subjects: 8
Study 1310645 — intervention group
Group type: COMPARATOR
Intervention: Cellulose (7 g)
Number of subjects: 8
Study 6239881 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastisol
Number of subjects: 19
Study 6239881 — intervention group
Group type: COMPARATOR
Intervention: compound tincture of benzoin
Number of subjects: 19
Study 30684600 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumbo forceps polypectomy (JFP)
Number of subjects: 169
Study 30684600 — intervention group
Group type: COMPARATOR
Intervention: Cold snare polypectomy (CSP)
Number of subjects: 169
Study 30684600 — intervention group
Group type: EXPERIMENTAL
Intervention: JFP for polyps >3 mm
Number of subjects: 169
Study 30684600 — intervention group
Group type: COMPARATOR
Intervention: CSP for polyps >3 mm
Number of subjects: 169
Study 26588236 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg/d
Number of subjects: 354
Study 26588236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study 27751589 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5mg oral paroxetine
Number of subjects: 80
Study 27751589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 25043905 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing a violent video game as a male avatar
Number of subjects: 242
Study 25043905 — intervention group
Group type: COMPARATOR
Intervention: Playing a violent video game as a female avatar
Number of subjects: 242
Study 22421064 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation with olanzapine (RIS+OLZ group)
Number of subjects: 26
Study 22421064 — intervention group
Group type: COMPARATOR
Intervention: Increased risperidone dose (RIS+RIS group)
Number of subjects: 26
Study 20697290 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncoated probiotic strains (5 x 10^9 CFU/strain/day for 21 days)
Number of subjects: 44
Study 20697290 — intervention group
Group type: EXPERIMENTAL
Intervention: Microencapsulated probiotic strains (1 x 10^9 CFU/strain/day for 21 days)
Number of subjects: 44
Study 18786039 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-theory-based interventions focusing on at-risk and older children, employing intervention specialists
Number of subjects: 26
Study 18786039 — intervention group
Group type: EXPERIMENTAL
Intervention: Single approach interventions
Number of subjects: 26
Study 18786039 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26